Guest Author : Ms.Ruby Kaul – Architecting Possibilities
More than two decades ago, when I walked into my first pharma sales meeting, I was among the few women among the room full of men. The silence was deafening. Today, leading a substantial team of sales professionals across India, I still encounter that silence in power rooms, but now I fill it with results, vision, and unwavering determination. This is my story, and the story of countless women quietly revolutionizing India’s pharmaceutical landscape by waking up at 5am while everyone sleeps.
Having climbed from territory sales executive to regional sales leader, I’ve witnessed how statistics reflect our harsh reality. Women constitute merely 11% of India’s pharmaceutical workforce, dropping to 5% in frontline sales and marketing. Despite women-led territories consistently delivering 15-20% higher growth rates, only 18% of senior healthcare positions are held by women. The 34% gender pay gap isn’t just unfair, it’s economically irrational when companies with women in leadership achieve 50% better profits.
The Institutional Challenges: Beyond Individual Barriers
Through three decades, I’ve identified four systemic challenges impeding women’s progress. Traditional hierarchical expectations often led healthcare professionals to seek senior confirmation for clinical presentations, inadvertently creating additional validation layers for women representatives. Meanwhile, crucial business relationships develop through informal networking, late-night strategy sessions and industry gatherings, where women’s participation remains limited, restricting access to career-defining opportunities. Companies frequently face the dilemma of balancing safety considerations with territorial assignments, often resulting in restricted coverage areas that inadvertently limit career progression. Additionally, performance evaluation systems sometimes require women to demonstrate consistently higher achievement metrics for equivalent recognition, creating unsustainable pressure cycles that contribute to talent attrition precisely when the industry needs diverse perspectives most.
The Business Case: Strategic Imperative, Not CSR
Managing P&L across therapeutic segments proves gender diversity delivers competitive advantage through superior market penetration, 25% higher customer retention rates, enhanced innovation adoption, and better crisis management. Yet most pharma companies operate with 80-90% male leadership teams.
Breaking Through: Strategic Solutions
Infrastructure Investment: Create safety protocols, flexible arrangements, and family support systems delivering measurable ROI through talent retention.
Mandate Inclusion: Formalize mentorship programs and women’s leadership councils. Supplement informal networks with institutional support.
Address Bias: Implement blind reviews, standardized criteria, and bias training. Companies see 40% improvement in women’s advancement rates.
Leverage Technology: Digital platforms eliminate traditional barriers in client engagement and territory management.
The Pioneers Who Paved the Way
My journey draws inspiration from Kiran Mazumdar-Shaw’s Biocon empire and leaders like Dr. Priya Nair at Abbott and Rashika Narain at Lupin, who succeeded because diverse perspectives brought innovative solutions male-dominated teams overlooked.
The Path Forward:
The industry’s transformation toward personalized medicine and digital health demands diverse thinking. This requires measurable diversity targets, transparent advancement pathways, women-specific leadership programs, and zero-tolerance bias policies.
Today, when I enter boardrooms, I’m no longer the only woman. Silence has become substantive dialogue; skepticism has yielded to earned respect. But this progress is just the beginning.
Women entering pharma today will inherit an industry where contributions are valued, voices heard, and leadership expected rather than exceptional. They’ll drive personalized medicine innovations, lead digital transformation, and build healthcare solutions serving India’s diverse population effectively.
This isn’t just about breaking glass ceilings, it’s about dismantling barriers and building something more inclusive, innovative, and successful. The pharmaceutical industry has always been about improving lives. It’s time we started with the talented women who make that mission possible. From being a woman in the room to being among the 11% ensuring wellness and healthcare reaching billions of Indians, achieving that would be a job well done.
Note:
Author, Ms. Ruby Kaul is a Senior Sales Leader with over two decades of experience in India’s pharmaceutical industry, having led teams across multiple therapeutic areas and geographic markets. She is recognized for building high-performing sales organizations and mentoring next generation leaders in pharma. Views are personal.
About The Author
What a great insight
Very informative!